Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

被引：0

作者：

Gonzalez-Cao, Maria

de las Casas, Clara Mayo

Oramas, Juana

Berciano-Guerrero, Miguel-Angel

De la Cruz, Luis

Cerezuela-Fuentes, Pablo

Arance, Ana Maria

Munoz-Couselo, Eva

Espinosa, Enrique

Puertolas, Teresa

Beveridge, Robert Diaz

Ochenduszko, Sebastian

Silva, Maria Jose Villanueva

Basterretxea, Laura

Bellido, Lorena

Rodriguez-Abreu, Delvys

Drozdowskyj, Ana

Vila, Miguel Angel Molina

Lopez-Martin, Jose Antonio

Berrocal, Alfonso

机构：

[1] Inst Oncol Dr Rosell, Barcelona, Spain

[2] Pangaea Oncol, Barcelona, Spain

[3] Hosp Univ Canarias, Tenerife, Spain

[4] HURyVV Hosp Univ Reg & Virgen Victoria Malaga, Unidad Intercentros Oncol, IBIMA Inst Invest Biomed Malaga, Malaga, Spain

[5] Hosp Univ Virgen Macarena, Seville, Spain

[6] Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain

[7] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[8] Vall dHebron Inst Oncol, Vall dHebron Hosp, Barcelona, Spain

[9] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain

[10] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain

[11] Hosp Univ & Politec La Fe, Valencia, Spain

[12] Hosp Univ Dr Peset, Valencia, Spain

[13] Complexo Hosp Univ Vigo, Vigo, Spain

[14] Hosp Univ Donostia, San Sebastian, Spain

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

[17] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Dept Oncol, Barcelona, Spain

[18] Hosp 12 Octubre, Madrid, Spain

[19] Hosp Gen Univ Valencia, Valencia, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9528

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9528

引用

页数：3

共 50 条

[41] A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.
Marshall, Ernest
Coupland, Sarah
Corrie, Philippa
Damato, Bertil
Danson, Sarah
Dobson, Lisa
Evans, T. R. Jeffry
Goodman, Andrew
Kalirai, Helen
Jones, Sarah
Kumar, Satish
Larkin, James M. G.
Lorigan, Paul
Nicholson, Steve
Ottensmeier, Christian
Silcocks, Paul
Steven, Neil
Tudur-Smith, Catrin
Nathan, Paul D.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[42] Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study (vol 15, pg 954, 2014)
Ribas, A.
Gonzalez, R.
Pavlick, A.
LANCET ONCOLOGY, 2014, 15 (10) : E417 - E417
[43] Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
Motzer, Robert J.
Hutson, Thomas E.
Olsen, Mark R.
Hudes, Gary R.
Burke, John M.
Edenfield, William J.
Wilding, George
Agarwal, Neeraj
Thompson, John A.
Cella, David
Bello, Akintunde
Korytowsky, Beata
Yuan, Jinyu
Valota, Olga
Martell, Bridget
Hariharan, Subramanian
Figlin, Robert A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (12) : 1371 - 1377
[44] Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation
Ascierto, Paolo Antonio
Flaherty, Keith
Queirolo, Paola
Sullivan, Ryan J.
Chlarlon-Sllenl, Vanna
Rldolfi, Rugger
Testori, Alessandro
Simeone, Ester
Grimaldi, Antonio Maria
Sabbatino, Francesco
Curvietto, Marcelio
Ciliberto, Gennaro
Botti, Gerardo
Mozzillo, Nicola
Ferrone, Soldano
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
Ribas, Antoni
Daud, Adil
Pavlick, Anna C.
Gonzalez, Rene
Lewis, Karl D.
Hamid, Omid
Gajewski, Thomas F.
Puzanov, Igor
Wongchenko, Matthew
Rooney, Isabelle
Hsu, Jessie J.
Yan, Yibing
Park, Erica
McArthur, Grant A.
CLINICAL CANCER RESEARCH, 2020, 26 (01) : 46 - 53
[46] A RANDOMIZED PHASE-I PHASE II STUDY OF CONTINUOUS VERSUS INTERMITTENT INTRAVENOUS INTERFERON-GAMMA IN PATIENTS WITH METASTATIC MELANOMA
ERNSTOFF, MS
TRAUTMAN, T
DAVIS, CA
REICH, SD
WITMAN, P
BALSER, J
RUDNICK, S
KIRKWOOD, JM
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (11) : 1804 - 1810
[47] Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.
Dummer, Reinhard
Flaherty, Keith
Robert, Caroline
Arance, Ana Maria
De Groot, Jan Willem
Garbe, Claus
Gogas, Helen
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Schadendorf, Dirk
Yamazaki, Naoya
Pickard, Michael D.
Zohren, Fabian
Edwards, Michelle L.
Ascierto, Paolo Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study
McArthur, G.
Gonzalez, R.
Pavlick, A.
Hamid, O.
Puzanov, I.
Gajewski, T. F.
Daud, A.
Yin, M.
Choong, N.
Ribas, A.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S856 - S857
[49] Update on Overall Survival in the COLUMBUS Study: A randomized Phase 3 Study of Encorafenib (ENCO) plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in Patients with BRAF V600 mutated Melanoma
Schadendorf, D.
Garbe, C.
Gutzmer, R.
Loquai, C.
Fluck, M.
Kiecker, F.
Mohr, P.
Terheyden, P.
Gogas, H. J.
Ascierto, P. A.
Flaherty, K. T.
Arance, A.
Mandala, M.
Liszkay, G.
Krajsova, I.
de Groot, J. W. B.
Dutriaux, C.
Gollerkeri, A.
Pickard, M. D.
Robert, C.
Dummer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 79 - 80
[50] A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).
Queirolo, Paola
de la Cruz Merino, Luis
Abajo Guijarro, Ana Maria
Tawbi, Hussein Abdul-Hassan
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →